Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Mathilde Chanut^{1

2}, Aurélie Cabannes-Hamy^{1

2}, Marie Balsat^{2

3

4}, Nassim Sahki⁵, Emmanuel Raffoux^{2

6}, Yosr Hicheri^{2

7}, Bruno Lioure^{2

8}, Lucie Laemmel^{2

9}, Thibaut Leguay^{2

9}, Victoria Cacheux^{2

10}, Maria Pilar Gallego-Hernanz^{2

11}, Andrea Pieragostini^{2

12}, Gabrielle Roth-Guepin^{2

13}, Ludovic Gabellier^{2

14}, Nathalie Denizon^{2

15}, Lise Willems^{2

16}, Quentin Cabrera^{2

17}, Sylvain Chantepie^{2

18}, Valérie Coiteux^{2

4

19}, Claudie Capdupuy^{2

20}, Martin Carré^{2

21}, Antoine Machet^{2

22}, Juliette Lambert¹, Sandrine Roux⁵, Franck-Emmanuel Nicolini^{4

23}, Nicolas Boissel^{2

24}, Emmanuelle Clappier^{2

25}, Rathana Kim^{2

25}, Philippe Rousselot^{1

2

4

26}

Affiliations

¹ Hematology Department, Centre Hospitalier de Versailles, Le Chesnay Rocquencourt, France.
² Group for Research on Adult Acute Lymphoblastic Leukemia, Paris, France.
³ Hematology Department, Lyon University Hospital, Lyon, France.
⁴ French Intergroup for Chronic Myelogenous Leukemia, Lyon, France.
⁵ Clinical Research Department, Centre Hospitalier de Versailles, Le Chesnay Rocquencourt, France.
⁶ Adult Hematology Department, St-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁷ Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
⁸ Department of Onco-Hematology, University of Strasbourg, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
⁹ Hematology Department, Bordeaux University Hospital, Pessac, France.
¹⁰ Hematology Department, Clermont-Ferrand University Hospital, Clermont Ferrand, France.
¹¹ Hematology Department, Poitiers University Hospital, Poitiers, France.
¹² Hematology Department, Dijon University Hospital, Dijon, France.
¹³ Hematology Department, Nancy University Hospital, Nancy, France.
¹⁴ Hematology Department, Montpellier University Hospital, Montpellier, France.
¹⁵ Hematology Department, Le Mans Hospital, Le Mans, France.
¹⁶ Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
¹⁷ Department of Onco-Hematology, La Réunion University Hospital, Saint Pierre, France.
¹⁸ Hematology Department, University Hospital, Caen, France.
¹⁹ Hematology Department, Lille University Hospital, Lille, France.
²⁰ Hematology Department, Côte Basque Hospital Center, Bayonne, France.
²¹ Hematology Department, Grenoble University Hospital, Grenoble, France.
²² Hematology Department, Tours University Hospital, Tours, France.
²³ Hematology Department, Centre Léon Berard, Lyon, France.
²⁴ Adolescent and Young Adult Hematology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
²⁵ Laboratory of Hematology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
²⁶ Unité de Formation et de Recherche Simone Veil, University Versailles Paris-Saclay, Montigny-le-Bretonneux, France.

PMID: 40601900
PMCID: PMC12452587
DOI: 10.1182/bloodadvances.2025016665

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Mathilde Chanut et al. Blood Adv. 2025.

. 2025 Sep 23;9(18):4580-4584.

doi: 10.1182/bloodadvances.2025016665.

Authors

Affiliations

¹ Hematology Department, Centre Hospitalier de Versailles, Le Chesnay Rocquencourt, France.
² Group for Research on Adult Acute Lymphoblastic Leukemia, Paris, France.
³ Hematology Department, Lyon University Hospital, Lyon, France.
⁴ French Intergroup for Chronic Myelogenous Leukemia, Lyon, France.
⁵ Clinical Research Department, Centre Hospitalier de Versailles, Le Chesnay Rocquencourt, France.
⁶ Adult Hematology Department, St-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁷ Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
⁸ Department of Onco-Hematology, University of Strasbourg, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
⁹ Hematology Department, Bordeaux University Hospital, Pessac, France.
¹⁰ Hematology Department, Clermont-Ferrand University Hospital, Clermont Ferrand, France.
¹¹ Hematology Department, Poitiers University Hospital, Poitiers, France.
¹² Hematology Department, Dijon University Hospital, Dijon, France.
¹³ Hematology Department, Nancy University Hospital, Nancy, France.
¹⁴ Hematology Department, Montpellier University Hospital, Montpellier, France.
¹⁵ Hematology Department, Le Mans Hospital, Le Mans, France.
¹⁶ Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
¹⁷ Department of Onco-Hematology, La Réunion University Hospital, Saint Pierre, France.
¹⁸ Hematology Department, University Hospital, Caen, France.
¹⁹ Hematology Department, Lille University Hospital, Lille, France.
²⁰ Hematology Department, Côte Basque Hospital Center, Bayonne, France.
²¹ Hematology Department, Grenoble University Hospital, Grenoble, France.
²² Hematology Department, Tours University Hospital, Tours, France.
²³ Hematology Department, Centre Léon Berard, Lyon, France.
²⁴ Adolescent and Young Adult Hematology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
²⁵ Laboratory of Hematology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
²⁶ Unité de Formation et de Recherche Simone Veil, University Versailles Paris-Saclay, Montigny-le-Bretonneux, France.

PMID: 40601900
PMCID: PMC12452587
DOI: 10.1182/bloodadvances.2025016665

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

**Figure 1.**
**Outcomes of patients treated with ASC.** (A) OS of patients with R/R Ph⁺ ALL/LBC-ALL treated with ASC. (B) OS of patients with R/R Ph⁺ ALL/LBC-ALL treated with ASC in combination (blue) or as monotherapy (red). (C) EFS of patients with R/R Ph⁺ ALL/LBC-ALL treated with ASC. (D) EFS of patients treated with ASC in combination (blue) or as monotherapy (red).

See this image and copyright information in PMC

References

1. Chalandon Y, Rousselot P, Chevret S, et al. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia. Blood. 2024;143(23):2363–2372. - PubMed
1. Morita K, Kantarjian HM, Sasaki K, et al. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021;127(15):2641–2647. - PubMed
1. Jabbour E, Kantarjian HM, Aldoss I, et al. Ponatinib vs imatinib in frontline Philadelphia chromosome–positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2024;331(21):1814–1823. - PMC - PubMed
1. Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Treat Options Oncol. 2019;20(1):4. - PMC - PubMed
1. Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733–737. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Affiliations

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Authors

Affiliations

Conflict of interest statement

Figures

References